

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/132547/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Muller, Ilaria , Taylor, Peter N. , Daniel, Rhian M. , Hales, Charlotte , Scholz, Anna, Candler, Toby, Pettit, Rebecca J., Evans, William D. , Shillabeer, Dionne, Draman, Mohd S., Dayan, Colin M. , Tang, Hiu K. C., Okosieme, Onyebuchi, Gregory, John W. , Lazarus, John H., Rees, D. Aled and Ludgate, Marian E. 2020. CATS II long-term anthropometric and metabolic effects of maternal sub-optimal thyroid function in offspring and mothers. *Journal of Clinical Endocrinology and Metabolism* 105 (7) , dgaal29. 10.1210/clinem/dgaal29

Publishers page: <http://dx.doi.org/10.1210/clinem/dgaal29>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



This is the peer reviewed version of the article found at <https://doi.org/10.1210/clinem/dgaa129>, published in final form in *The Journal of Clinical Endocrinology & Metabolism*, Vol. 105, Issue 7, July 2020, dgaa129, online 12 May 2020 at <https://academic.oup.com/jcem/article-abstract/105/7/dgaa129/5836234>. This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record."

**1 CATS II long-term anthropometric and metabolic effects of maternal sub-optimal
2 thyroid function in offspring and mothers**

3

4 Ilaria Muller^{1,2}, Peter N Taylor¹, Rhian M Daniel³, Charlotte Hales¹, Anna Scholz¹, Toby
5 Candler⁴, Rebecca J Pettit⁵, William D Evans⁵, Dionne Shillabeer¹, Mohd S Draman^{1,6}, Colin
6 M Dayan¹, Hiu K C Tang^{1,7}, Onyebuchi Okosieme¹, John W Gregory³, John H Lazarus¹, D
7 Aled Rees⁸, Marian E Ludgate¹

8 ¹ Thyroid Research Group, Division of Infection & Immunity, School of Medicine, Cardiff
9 University, UK

10 ² Department of Endocrinology, Fondazione IRCCS Ca' Granda Ospedale Maggiore
11 Policlinico, Milan, Italy

12 ³ Division of Population Medicine, School of Medicine, Cardiff University, UK

13 ⁴ MRC The Gambia at the London School of Hygiene and Tropical Medicine, London, UK

14 ⁵ Radiology, Medical Physics and Clinical Engineering Directorate, University Hospital of
15 Wales, Cardiff, UK

16 ⁶ Faculty of Medicine, University Sultan Zainal Abidin, Terengganu, Malaysia

17 ⁷ Department of Oncology, Nottingham University NHS Trust, Nottingham, UK

18 ⁸ Neuroscience and Mental Health Research Institute, School of Medicine, Cardiff University,
19 UK

20 **SHORT TITLE:** Maternal thyroid function effects on metabolism

21 **KEYWORDS:** thyroid, pregnancy, metabolism, obesity, hypothyroidism, BMI

22 **DISCLOSURE SUMMARY:** The authors have nothing to disclose.

23 **CLINICAL TRIAL REGISTRATION NUMBER (CATS-I):** ISRCTN46178175

24 **FUNDED BY:** The Charles Wolfson Trust (grant to ML), Action Medical Research (project
25 code GN2033, grant to ML), The Henry Smith Charity (project code 20122759 GN 2033,
26 grant to ML) and The American Thyroid Association (project code ATA-2014-033.R1, grant
27 to PNT).

28 **ABSTRACT**

29 **CONTEXT & OBJECTIVES.** The Controlled Antenatal Thyroid Screening study-I
30 (CATS-I) was a randomized controlled trial investigating the effects of levothyroxine therapy
31 for suboptimal gestational thyroid function (SGTF), comparing outcomes in children of
32 treated (SGTF-T) with untreated (SGTF-U) women during pregnancy. This follow-up study
33 CATS-II reports the long-term effects on anthropometric, bone and cardiometabolic
34 outcomes in mothers and offspring, and includes a group with normal gestational thyroid
35 function (NGTF).

36 **DESIGN & PARTICIPANTS.** 332 mothers (197 NGTF, 56 SGTF-U, 79 SGTF-T) aged
37 41.2 ± 5.3 years (mean \pm SD) and 326 paired children assessed 9.3 ± 1.0 years after birth for: 1)
38 body mass index (BMI); 2) lean, fat and bone mass by dual-energy x-ray absorptiometry; 3)
39 blood pressure, augmentation index and aortic pulse-wave-velocity; 4) thyroid function,
40 lipids, insulin and adiponectin. The difference between group means was compared using
41 linear regression.

42 **RESULTS.** Offspring's measurements were similar between groups. Although maternal BMI
43 was similar between groups at CATS-I, after 9-years (at CATS-II) SGTF-U mothers showed
44 higher BMI (median[IQR] $28.3[24.6-32.6]$ kg/m²) compared with NGTF ($25.8[22.9-30.0]$
45 kg/m², $p=0.029$), driven by fat mass increase. At CATS-II SGTF-U mothers also had higher
46 TSH values (median[IQR] $2.45[1.43-3.50]$ mU/L) than NGTF ($1.54[1.12-2.07]$ mU/L;
47 $p=0.015$), since 64% had never received levothyroxine. At CATS-II SGTF-T mothers had
48 BMI ($25.8[23.1-29.8]$ kg/m², $p=0.672$) and TSH ($1.68[0.89-2.96]$ mU/L; $p=0.474$) values
49 similar to NGTF mothers.

50 **CONCLUSIONS.** Levothyroxine supplementation of women with SGTF did not affect long-
51 term offspring anthropometric, bone and cardiometabolic measurements. However, absence

52 of treatment was associated with sustained long-term increase in BMI and fat mass in women
53 with SGTF.

54

55 **PRÉCIS**

56 Levothyroxine for suboptimal gestational thyroid function did not affect offspring's
57 anthropometric, bone and cardiometabolic outcomes, but prevented an increase in maternal
58 fat mass over 9 years.

59 INTRODUCTION

60 Pregnancy induces physiological changes in the maternal hypothalamic-pituitary-
61 thyroid axis, such that interpretation of thyroid function during pregnancy must take into
62 account trimester-specific reference ranges (1, 2). Suboptimal gestational thyroid function
63 (SGTF), defined as a low free thyroxine (FT4) concentration and/or raised thyroid-
64 stimulating hormone (TSH), is common and associated with adverse pregnancy and offspring
65 outcomes (1, 3, 4).

66 Overt hypothyroidism is well-known to be associated with impaired fetal
67 neurodevelopment, particularly during the first trimester of pregnancy when the fetus is
68 entirely dependent on maternal thyroid hormone production for optimal brain development
69 (1, 2, 5). However, the effects of mild maternal thyroid dysfunction are less clear. Whereas
70 isolated hypothyroxinemia has been found to be associated with impaired developmental and
71 neurobehavioral outcomes (1, 6), including verbal delay (7), autism (8, 9) and attention-
72 deficit/hyperactivity disorder (ADHD) (10-14) in offspring, such effects have not been
73 described for maternal subclinical hypothyroidism (1, 15-17).

74 Whilst many studies have examined effects on neuro-intellectual and behavioral
75 outcomes, very little is known about the effects of maternal gestational thyroid dysfunction
76 on offspring anthropometric, bone and cardiometabolic outcomes. Both high TSH levels and
77 low FT4 levels during gestation are known to be associated with maternal weight gain and
78 adverse metabolic pregnancy outcomes (18-20); accordingly, pregnancy-specific reference
79 ranges for thyroid function assessments are influenced by body mass index (BMI) (21-23). In
80 turn, maternal overweight and obesity during gestation and an excessive gestational weight
81 gain, especially during early gestation, are associated with long-term adverse anthropometric
82 and cardiometabolic outcomes in offspring (24-26). Overt hypothyroidism and
83 hyperthyroidism negatively affect bone mass maintenance (27, 28); such effects have also

84 been observed in long-term subclinical hyperthyroidism, but not hypothyroidism (29-31),
85 with only isolated exceptions (32). Thyroid hormones are also a determinant for bone
86 development and skeletal maturation; it is well known that children with impaired and
87 untreated thyroid function have short stature (28).

88 The Controlled Antenatal Thyroid Screening (CATS) study I (CATS-I) was the first
89 randomized controlled trial to investigate the effects of antenatal screening and treatment of
90 SGTF on offspring cognitive function (15). No effects on intelligence quotient (IQ) of 3 year-
91 old offspring were found, and a follow-up study (CATS-II) repeating IQ assessment at age 9
92 (33) confirmed similar findings (17). CATS-II also allowed us to extend the phenotyping of
93 children to other outcomes known to be influenced by thyroid status. We recently reported
94 adverse behavioral outcomes in children born to mothers exposed to excess levothyroxine
95 replacement (34).

96 Here we present for the first time the effects of treatment for SGTF on maternal and
97 child anthropometric, bone and cardiometabolic outcomes, evaluated 9 years after delivery.
98 We included the maternal analysis as a reference population for their paired children, and as a
99 valuable cohort followed long-term to better evaluate the association between
100 mild/subclinical thyroid dysfunction and overweight/obesity among adult women (35-37), as
101 well as adverse cardiovascular events (38-41).

102 **MATERIALS AND METHODS**

103 **STUDY DESIGN AND POPULATION**

104 As previously reported, CATS-II (17, 33, 34) is the follow-up study of CATS-I
105 (ISRCTN 46178175) (15). Briefly, in CATS-I a total of 21,846 pregnant women (median
106 gestation of 12 weeks 3 days) were randomized to have their thyroid function measured at

107 recruitment (screening group) or at the end of pregnancy (control group). Those in the
108 screening group diagnosed with SGTF, defined as FT4 <2.5th percentile and/or TSH >97.5th
109 percentile of the cohort, were commenced on levothyroxine treatment (SGTF-T) for the
110 duration of their pregnancy, while the women with SGTF in the control group were left
111 untreated (SGTF-U) and subsequently referred to their general practitioner for further
112 management following delivery. In the SGTF-T group, the starting dose of levothyroxine was
113 150µg daily; TSH and FT4 measurements were repeated after 6 weeks from commencing
114 treatment and at 30 weeks of gestation, with adjustment of levothyroxine dose where
115 necessary, aiming to maintain TSH levels in the 0.1-1.0mIU/L range. In CATS-I the IQ of
116 children of SGTF-T and SGTF-U mothers was measured at age 3 years (15). The follow-up
117 study (CATS-II) repeated IQ assessment in 9-year-old offspring (17, 33), included UK
118 participants only and also evaluated children of women with normal gestational thyroid
119 function (NGTF) during CATS-I. In addition to IQ assessment (17) other outcomes were also
120 evaluated, including child behavior (34) and the anthropometric, bone and cardiometabolic
121 measurements presented here. At CATS-II recruitment, clinical data including history of
122 levothyroxine treatment following CATS-I were collected. The overall study design and
123 population is summarized in **Figure 1**.

124 **BMI AND BMI SDS**

125 Standing heights were measured to the nearest 0.1 cm using a Harpenden stadiometer
126 (Holtain Ltd, Crymych, UK). Participants were weighed to the nearest 0.1 kg in lightweight
127 clothing without shoes, using the weighing function of a Body Fat Analyzer (TBF-305;
128 Tanita, Tokyo, Japan). Body mass index (BMI) was calculated as weight (kg) divided by
129 height (m) squared. Children's BMI standard deviation scores (SDS) were calculated using
130 the UK reference population established in 1990 (42, 43).

131 **DXA SCAN ANALYSIS**

132 Whole body less head (WBLH), total lumbar spine (L1-L4) and left hip
133 measurements of bone and/or lean and fat mass were made in 327/332 (98.5%) mothers and
134 323/326 (99.1%) children using a Hologic QDR Explorer fan-beam dual-energy x-ray
135 absorptiometry (DXA) scanner (Hologic Inc., Marlborough, USA). Subjects were assessed in
136 the supine position, in the fasted state and after bladder emptying. Whole body scans were
137 acquired in explorer (e) mode, equivalent to array mode, while spine and hip scans were
138 acquired in survey (s) mode, equivalent to fast array. Scans were analyzed using Hologic
139 software V 13.3.0.1:3 with the auto low-density option being applied to the spine scans where
140 appropriate.

141 For bone analysis, bone area (cm²), bone mineral content (BMC, g) and the BMC per
142 unit area of bone (bone mineral density [BMD], g/cm²) were assessed. In particular, for
143 mothers the BMD values of femoral neck (FN-BMD) and total lumbar spine (LS-BMD) were
144 compared across the subject groups. For children DXA bone mineral measurements are
145 strongly influenced by several factors including sex, chronological and skeletal age, height,
146 weight, ethnicity and pubertal development (44-48). In order to reduce such biases, the bone
147 mineral apparent density (BMAD) was also considered; it was calculated for the femoral
148 neck (FN) using the method of Lu et al. (49), and for the lumbar spine (LS) using the
149 geometric assumptions made by Carter et al (50), but estimating the volume of each
150 individual vertebral body (L1–L4) from its bone area and summing the result rather than the
151 total volume of L2–L4 (51). Depending on the body region studied (LS, FN, WBLH), BMD
152 and BMAD were expressed as standard deviation scores (SDS) compared to the UK
153 population (cohorts of the Ward study [W] or the Alphabet study [A]) (51, 52) and the US
154 population (Hologic manufacturer [H]), for a total of 8 measurements.

155 For body composition, absolute WBLH fat and lean mass (kg), as well as relative fat

156 mass (%), were measured.

157 **BIOCHEMICAL ANALYSIS**

158 Fasting blood samples were collected from 294/332 (88.5%) mothers but only 83/326
159 (25.5%) children, since most of them refused phlebotomy. Serum was prepared by
160 centrifugation at 4500 rpm for 10 minutes at +4°C, and stored at -80°C until analysis.

161 Thyroid-stimulating hormone (TSH), free-thyroxine (FT4), free-triiodothyronine
162 (FT3), autoantibodies to thyroid peroxidase (TPOAb), triglyceride, total cholesterol, high-
163 density lipoprotein (HDL) cholesterol and insulin were measured by Chemiluminescent
164 Microparticle Immunoassay (Architect® System, Abbott Laboratories, USA). Normal
165 reference ranges for thyroid function (females aged above 18 years) were 0.30 – 4.4 mIU/L
166 for TSH, 9.0 – 19.1 pmol/L for FT4 and 2.6 – 5.7 pmol/L for FT3. According to the assay
167 cut-off, TPOAb values were considered positive if ≥ 6 IU/ml and negative if < 6 IU/ml.

168 High molecular weight adiponectin (APN) was measured by ELISA (EMD Millipore,
169 Billerica, MA, USA).

170 **CARDIOVASCULAR FUNCTION**

171 The Vicorder device (Skidmore Medical, UK), a non-invasive cuff-based oscillometric
172 technique that simultaneously measures the upstroke of femoral and carotid pulsations, was
173 used to calculate the aortic pulse wave velocity (PWV), a measure of arterial stiffness (53), in
174 addition to other measurements of peripheral and central blood pressure. This technique is
175 reproducible (54), validated in both adults (55, 56) and children (57, 58) and agrees closely
176 with invasive measures of central blood pressure (59). All measurements were performed by
177 a single trained operator (DS). Measurements were taken with subjects relaxed in a quiet
178 room, and with the head raised to 30°. Aortic PWV was measured by cuffs placed over the
179 right carotid and the right thigh, with the length between the two arteries determined using a

180 tape measure placed over the suprasternal notch and the mid-point of the thigh cuff.
181 Measurements were recorded when the pressure waveforms were reproducible over both
182 arteries. Additional measurements were undertaken with the cuff placed on the right upper
183 arm, including the systolic blood pressure (SP), the diastolic blood pressure (DP) and the
184 aortic augmentation index (AI), a measure of the pulse wave reflection influenced by vessel
185 stiffness (53).

186 **DATA ANALYSIS**

187 Histograms were performed to assess the distribution of variables. Variables were
188 summarized using the sample mean \pm standard deviation (SD) if approximately normally
189 distributed, or using the sample median and interquartile range (IQR) otherwise. In addition,
190 variables judged to be right-skewed were log-transformed for inclusion in analyses.
191 Categorical variables (i.e. TPOAb positivity and child sex) were summarized using
192 percentages, and the statistical significance of associations between them calculated using
193 Fisher's exact test.

194 The effects of SGTF were first estimated comparing NGTF versus SGTF-U (p1U)
195 and NGTF versus SGTF-T (p1T) in an unadjusted linear regression model (Model 1) and
196 then adjusting for age, sex (children analysis only), ethnicity, socioeconomic status (defined
197 in (17)) and smoking during pregnancy (Model 2). The same analysis was repeated
198 comparing SGTF-U versus SGTF-T (p2) using linear regression adjusting for all the
199 variables included in Model 2 and additionally baseline (at CATS-I) values of TSH and FT4
200 (Model 3).

201 In the CATS-I study the FT4 levels of SGTF-T mothers repeated at either 20 or 30
202 weeks of gestation were classified as optimal (SGTF-Topt) or suggestive for possible
203 levothyroxine overtreatment (SGTF-Tover), if respectively below or above the threshold of

204 17.7 pmol/l, calculated as the top 2.5th percentile of the entire CATS-I UK population at
205 recruitment (15, 34). The analysis of Model 3 was then repeated for the SGTF-Topt and
206 SGTF-Tover subgroups. In the children's analysis, adjustment was additionally made for the
207 corresponding variable in the mother, where available.

208 **Supplemental Table 1** summarizes the Models used for each analysis (60). The data
209 were analyzed in STATA, version 12. Obtained p values <0.05 were considered statistically
210 significant.

211 **RESULTS**

212 **CHILDREN**

213 The female:male ratio was similar among the NGTF, SGTF-U and SGTF-T groups,
214 whereas the children of NGTF women were slightly older (by a few months only) than
215 SGTF-U and SGTF-T as previously reported (17, 34) (**Table 1**); thus age and sex were
216 included in all regression models.

217 No differences were observed between NGTF, SGTF-U and SGTF-T groups in BMI
218 SDS or any of the DXA or cardiovascular measurements (**Table 1**). Of note, the BMI SDS
219 scores were approximately 0.5 SD higher than the UK 1990 reference population (42, 43).

220 All biochemical measurements were similar among groups except for HDL
221 cholesterol (**Table 1**), which was marginally lower in the SGTF-T group compared with
222 SGTF-U (p=0.048).

223 **MOTHERS**

224 **Anthropometric, bone and cardiometabolic outcomes**

225 **Table 2** summarizes the results obtained among mothers: SGTF-T were slightly
226 younger (39.7 ± 4.8 years) compared with NGTF (41.2 ± 5.5 years; $p=0.002$), but had a
227 similar age to SGTF-U (40.9 ± 4.7 years; $p=0.144$). Untreated mothers (SGTF-U) had a
228 higher BMI (median: 28.3, IQR: [24.6 - 32.6] kg/m^2) compared with NGTF mothers (25.8
229 [22.9 - 30.0] kg/m^2 ; $p=0.029$); in contrast, the BMI of treated mothers (SGTF-T) was similar
230 to NGTF mothers (25.8 [23.1 - 29.8] kg/m^2 ; $p=0.672$). Importantly, BMI at CATS-I did not
231 differ across the three groups (**Figure 2**): NGTF 25.0 [22.4 - 28.3] kg/m^2 , SGTF-U 26.0 [23.4
232 - 30.1] kg/m^2 ($p=0.111$), SGTF-T 25.6 [23.0 - 29.2] kg/m^2 ($p=0.112$). When additionally
233 adjusted for BMI at entry into CATS-I, the difference in BMI at CATS-II between SGTF-U
234 and NGTF mothers remained significant ($p=0.040$). DXA analysis showed that the BMI
235 increase was attributable to an increase in fat, but not lean mass (**Table 2, Figure 2**). DXA
236 analysis showed no difference in BMD calculated at the femoral neck, total lumbar spine or
237 whole body less head.

238 Among the metabolic measurements, SGTF-U mothers had higher triglyceride levels
239 (median: 1.01, IQR: [0.78-1.40] mmol/L) than NGTF mothers (0.90 [0.70-1.10] mmol/L ;
240 $p=0.041$). Fasting insulin levels were also higher in SGTF-U mothers (6.30 [4.40-9.15]
241 $\mu\text{IU/ml}$) than SGTF-T mothers (5.50 [3.85-7.15] $\mu\text{IU/ml}$; $p=0.046$). However, when BMI was
242 included in the regression models the between-group significance was lost ($p=0.212$ and
243 $p=0.169$ respectively).

244 There was no difference in any of the cardiovascular measurements between groups.

245 **Thyroid function**

246 As expected, a higher percentage of SGTF-U (20/50, 40%) and SGTF-T (38/71, 53%)
247 mothers were TPOAb positive, compared with NGTF mothers (21/173, 12%; $p<0.001$; **Table**

248 2). Importantly, SGTF-U mothers at recruitment to CATS-II had significantly higher TSH
249 levels (median [IQR]: 2.45 [1.43-3.50] mU/L) compared with NGTF mothers (1.54 [1.12-
250 2.07] mU/L; $p=0.015$); TSH levels were also higher compared with SGTF-T mothers, albeit
251 not quite reaching statistical significance (1.68 [0.89-2.96] mU/L; $p=0.070$). However, TSH
252 concentrations were not different between SGTF-U and SGTF-T mothers at CATS-I
253 recruitment (3.37 [1.22-4.45] mU/L and 4.21 [2.33-5.23] mU/L respectively, $p=0.098$).
254 SGTF-T mothers had FT4 levels within the normal range (15.0 ± 2.9) in the CATS-II study,
255 although these were significantly higher than in the NGTF group (13.6 ± 1.7 ; $p<0.001$).

256 The clinical history revealed that the majority of SGTF-U women had never been
257 treated with levothyroxine, in contrast to those from the SGTF-T group, half of whom at
258 recruitment to CATS-II were still on treatment commenced during CATS-I (**Table 3**). Of
259 note, when TSH values were included in the regression model for BMI, the significance
260 between SGTF-U and NGTF was lost ($p=0.131$).

261 Furthermore, TSH and BMI correlated positively in mothers in CATS-I ($p=0.037$),
262 but only when excluding the SGTF-T group in CATS-II ($p=0.027$; **Supplemental Figure 1**)
263 (60).

264 LEVOTHYROXINE OVER-TREATMENT SUBANALYSIS

265 Mothers

266 As shown in **Supplemental Table 2** (60), at CATS-II SGTF-T_{opt} ($n= 58$) and SGTF-T_{over}
267 ($n= 21$) women had similar thyroid function ($p=0.962$ for TSH levels), however SGTF-T_{over}
268 had lower BMI ($p=0.002$), absolute fat mass ($p=0.007$), lean mass ($p<0.001$), systolic blood
269 pressure ($p=0.036$) and higher HDL cholesterol levels ($p=0.002$) compared with SGTF-T_{opt}
270 (60). When including BMI in the regression models, the between-group significance was lost

271 for fat mass ($p=0.882$) and systolic blood pressure ($p=0.074$), but not for HDL cholesterol
272 ($p=0.022$) and lean mass ($p=0.003$).

273 SGTF-T_{over} women had lower BMI ($p=0.001$) and height ($p=0.032$) already at CATS-I,
274 such that the difference in BMI at CATS-II between SGTF-T_{opt} and SGTF-T_{over} lost
275 significance when adjusted for baseline BMI at CATS-I ($p=0.267$).

276 **Children**

277 As shown in **Supplemental Table 3** (60), there were no differences in terms of age
278 ($p=0.516$) and sex ($p=0.260$) between SGTF-T_{opt} ($n= 57$) and SGTF-T_{over} ($n= 21$) offspring.
279 However, similarly to their mothers, SGTF-T_{over} children had lower height ($p=0.016$), BMI
280 SDS ($p=0.001$) and lean mass ($p=0.004$) compared with SGTF-T_{opt} children, as well as FN-
281 BMD-H ($p=0.037$), WBLH-BMD-H ($p=0.002$) and WBLH-BMD-A ($p=0.002$). Of note,
282 when adjusting for the corresponding maternal measurement (p^5 column, **Supplemental**
283 **Table 3**), only BMI SDS ($p=0.006$) and height ($p=0.044$) remained significantly lower in
284 SGTF-T_{over} children compared with SGTF-T_{opt} children (60). When also adjusting for
285 paternal height, the difference in height between SGTF-T_{over} and SGTF-T_{opt} children lost
286 significance ($p=0.298$).

287 **DISCUSSION**

288 To our knowledge, the present study is the first to evaluate several long-term
289 anthropometric, bone and cardiometabolic outcomes in children and mothers from a large
290 cohort of women with SGTF randomized to receive levothyroxine treatment during
291 pregnancy.

292 No significant effects were observed on offspring outcomes evaluated at 9 years of age.
293 Only a slight reduction in HDL cholesterol levels was observed among children of treated
294 mothers compared with those who were untreated, albeit this was of marginal clinical

295 significance. Considering the additional limitation of the low number of children consenting
296 to phlebotomy, further studies in larger cohorts are needed before any firm conclusions can
297 be drawn in this context. It was noteworthy that the children's BMI was higher compared
298 with the UK children reference population established 30 years ago; this is in line with the
299 global secular trends in rates of childhood overweight and obesity observed over the last
300 three decades, as a likely consequence of unhealthy lifestyle (61, 62).

301 Long-term maternal bone and cardiovascular outcomes were also unaffected by SGTF,
302 whether treated or not. However, BMI was significantly greater at 9 years follow-up only in
303 the group of mothers with SGTF who had not been randomized during CATS-I to receive
304 levothyroxine replacement (SGTF-U), with DXA analysis showing that this weight gain was
305 predominantly attributable to an increase in fat rather than lean mass. On the contrary, the
306 group of mothers with SGTF who were started on levothyroxine replacement during CATS-I
307 (SGTF-T), 9 years later had similar BMI and fat mass values to women with NGTF. Of note,
308 the baseline BMI at enrolment into the CATS-I study was similar among all groups and,
309 when included in the regression model, did not influence the BMI change observed at CATS-
310 II. These observations suggest that the BMI increase had occurred in the 9-year time window
311 from recruitment into CATS-I and CATS-II, and only in the group of women with untreated
312 SGTF at CATS-I. In line with the higher prevalence of overweight and obesity in the SGTF-
313 U group, these women also had significantly higher triglyceride and insulin levels; however,
314 these differences lost significance when adjusted for BMI, suggesting that these metabolic
315 alterations were driven by overweight/obesity as expected (63-65). Untreated SGTF women
316 also had current higher TSH concentrations compared with the other two groups, since the
317 majority of them had not been commenced on levothyroxine treatment during CATS-I or the
318 following 9 years. On the contrary, nearly half of women with SGTF commencing
319 levothyroxine at CATS-I (SGTF-T) were still on treatment 9 years later; their higher FT4

320 levels likely reflected the measurement of exogenous T4 (66), especially if blood was
321 withdrawn after taking levothyroxine (67). The fact that the differences in BMI among
322 groups lost significance when adjusted for current TSH levels, suggests that the increase in
323 fat mass was largely driven by untreated suboptimal thyroid function. In this study other
324 BMI-influencing factors such as physical activity, dietary habits and family history for
325 obesity were not evaluated, thus their hypothetical influence on observed BMI differences
326 among groups cannot be excluded. However SGTF-U and SGTF-T women had been
327 randomised at CATS-I, thus we assume that confounding factors, other than those related to
328 thyroid function, should not differ between these groups. SGTF-T and NGTF women at
329 CATS-II presented similar values of thyroid and metabolic outcomes (TSH, BMI, fat mass,
330 triglyceride, insulin), parameters that were different only in the SGTF-U group. This
331 difference was statistically significant only when comparing SGTF-U and NGTF women but
332 not SGTF-U and SGTF-T women, with the sole exception of insulin levels, likely due to the
333 small size of SGTF-T group (N=79) compared with NGTF group (N=197).

334 Small variation in TSH levels even within the normal reference range is positively
335 associated with higher BMI and weight gain in other cohorts (68-71), and such a relationship
336 is bilateral (35-37). Obesity, likely acting via leptin, activates the hypothalamic-pituitary-
337 thyroid axis and induces a consequent rise in TSH levels (72, 73). On the other hand,
338 impaired thyroid function favors weight gain due to the consequent myxoedema and
339 reduction of resting energy expenditure (REE), particularly in overt hypothyroidism (37).
340 However, even smaller variations of thyroid function, usually considered clinically
341 insignificant, induce measurable REE modifications, and therefore if sustained have the
342 potential to affect body weight (74). Accordingly, in our study women with long-term
343 suboptimal thyroid function, if left untreated experienced increased body weight and fat

344 mass, while those who were treated did not. This suggests that in our cohort thyroid function
345 determined BMI and not vice versa.

346 A recent meta-analysis did not highlight any benefits on several outcomes, including
347 BMI, of levothyroxine treatment for subclinical hypothyroidism (75). However, this analysis
348 included a very large trial evaluating subjects above 65 years of age (76), which represents a
349 population that may not be comparable with younger individuals such as those analyzed in
350 our study. With respect to specific effects on BMI, the majority of studies were small-scale
351 and based on shorter follow-up periods (75), therefore not allowing definitive conclusions.
352 The study of Zhao et al (77) was one of the largest randomized trials of levothyroxine
353 replacement, enrolling 369 middle-aged males and females affected with subclinical
354 hypothyroidism who were followed-up for 15 months. In line with the results of our study,
355 subjects receiving levothyroxine showed a significant BMI reduction at the end of the follow-
356 up period, while untreated subjects did not. Clearly, further randomized trials are needed to
357 clarify the benefits of levothyroxine replacement on BMI in individuals affected with
358 subclinical hypothyroidism below 65 years of age.

359 Our exploratory sub-analysis showed that women exposed to over-replacement with
360 levothyroxine during pregnancy (SGTF-T_{over}), at CATS-II displayed lower BMI, height,
361 absolute fat mass, lean mass, SP and higher HDL values compared with those with optimal
362 gestational FT4 levels (SGTF-T_{opt}); fat mass and blood pressure seemed to be driven by BMI.
363 However, SGTF-T_{over} women were noted to have been thinner and shorter from baseline,
364 before commencing levothyroxine treatment during CATS-I; in fact when including baseline
365 BMI in the regression model, the BMI change observed at CATS-II lost significance.
366 Furthermore, levothyroxine doses were promptly reduced during CATS-I to correct the raised
367 FT4 levels, such that thyroid function of the SGTF-T_{over} group at CATS-II was normal and
368 similar to SGTF-T_{opt}. Considering that all women were commenced on a standard 150 µg

369 dose of levothyroxine during pregnancy, it is appropriate to conclude that this likely induced
370 an excessive increase of FT4 levels in this subgroup of thinner women, since they would
371 have required a smaller dose. This study further highlights the importance of adjusting
372 levothyroxine treatment for body weight, especially during pregnancy where high FT4 levels
373 have been associated with several negative outcomes (1, 2, 6), including a higher prevalence
374 of behavioral difficulties in the offspring of this cohort (34). Similar to their mothers, SGTF-
375 T_{over} children were thinner and shorter compared to SGTF-T_{opt} children. However, correction
376 for the corresponding maternal and paternal measurements, where available, reduced or
377 totally eliminated the between-group significance, indicating a genetic component rather than
378 an effect of levothyroxine overtreatment on anthropometric outcomes.

379 The strengths of our study include the large sample size, baseline randomization, analysis
380 of several anthropometric, bone and cardiometabolic outcomes, and longitudinal design with
381 one of the longest available follow-up periods. Our study has limitations, however, including
382 a lack of detailed information about the levothyroxine doses used and the length of drug
383 withdrawal periods during the 9 years between CATS-I and CATS-II, as well as a lack of
384 correction for other BMI-influencing factors, such as dietary habits, physical activity and
385 family history for obesity.

386 In conclusion, for the first time we evaluated the long-term effects of SGTF and treatment
387 with levothyroxine during pregnancy on a series of offspring anthropometric, bone and
388 cardiometabolic measurements, finding no significant evidence for benefit or harm. Women
389 with long-term untreated mild suboptimal thyroid function persisting after pregnancy showed
390 a significant increase in BMI, fat mass, triglyceride and insulin levels, that were absent in the
391 group of women treated with levothyroxine. Our study also emphasizes the need for careful
392 adjustment of levothyroxine dose for bodyweight to avoid overtreatment, especially during
393 pregnancy. Our findings thus highlight the need for dedicated large-scale randomized trials to

394 investigate the long-term benefits of levothyroxine treatment in young and middle-aged
395 individuals with suboptimal thyroid function, whether in relation to pregnancy or not. If our
396 observations were confirmed, the current indications to such treatment may need to be
397 revised.

398

399 **ACKNOWLEDGMENTS**

400 CATS-II was funded by The Charles Wolfson Trust (grant to ML), Action Medical Research
401 (project code GN2033, grant to ML), The Henry Smith Charity (project code 20122759 GN
402 2033, grant to ML) and The American Thyroid Association (project code ATA-2014-033.R1,
403 grant to PNT). We are extremely grateful to the children, parents and families who
404 participated in the study. Special thanks are extended to Julie Pell, Julie Evans, Sophie Fuller
405 and Beverley Carey for their dedicated support of the CATS project.

406 **REFERENCES**

- 407 1. Korevaar TIM, Medici M, Visser TJ, Peeters RP. Thyroid disease in pregnancy: new
408 insights in diagnosis and clinical management. *Nat Rev Endocrinol.* 2017;13:610-622.
- 409 2. Muller I, Taylor PN, Lazarus JH. Thyroid function in pregnancy. *Annals of Thyroid.*
410 2018;3:27.
- 411 3. Lazarus J, Brown RS, Daumerie C, Hubalewska-Dydejczyk A, Negro R, Vaidya B. 2014
412 European thyroid association guidelines for the management of subclinical
413 hypothyroidism in pregnancy and in children. *Eur Thyroid J.* 2014;3:76-94.
- 414 4. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid
415 Association for the Diagnosis and Management of Thyroid Disease During Pregnancy
416 and the Postpartum. *Thyroid.* 2017;27:315-389.
- 417 5. Haddow JE, Palomaki GE, Allan WC, et al. Maternal thyroid deficiency during pregnancy
418 and subsequent neuropsychological development of the child. *N Engl J Med.*
419 1999;341:549-555.
- 420 6. Korevaar TI, Muetzel R, Medici M, et al. Association of maternal thyroid function during
421 early pregnancy with offspring IQ and brain morphology in childhood: a population-
422 based prospective cohort study. *Lancet Diabetes Endocrinol.* 2016;4:35-43.
- 423 7. Henrichs J, Bongers-Schokking JJ, Schenk JJ, et al. Maternal thyroid function during early
424 pregnancy and cognitive functioning in early childhood: the generation R study. *J Clin*
425 *Endocrinol Metab.* 2010;95:4227-4234.
- 426 8. Roman GC, Ghassabian A, Bongers-Schokking JJ, et al. Association of gestational
427 maternal hypothyroxinemia and increased autism risk. *Ann Neurol.* 2013;74:733-742.


- 428 9. Andersen SL, Laurberg P, Wu CS, Olsen J. Attention deficit hyperactivity disorder and
429 autism spectrum disorder in children born to mothers with thyroid dysfunction: a Danish
430 nationwide cohort study. *BJOG*. 2014;121:1365-1374.
- 431 10. Vermiglio F, Lo Presti VP, Moleti M, et al. Attention deficit and hyperactivity disorders
432 in the offspring of mothers exposed to mild-moderate iodine deficiency: a possible novel
433 iodine deficiency disorder in developed countries. *J Clin Endocrinol Metab*.
434 2004;89:6054-6060.
- 435 11. Ghassabian A, Bongers-Schokking JJ, Henrichs J, et al. Maternal thyroid function during
436 pregnancy and behavioral problems in the offspring: the generation R study. *Pediatr Res*.
437 2011;69:454-459.
- 438 12. Pakkila F, Mannisto T, Pouta A, et al. The impact of gestational thyroid hormone
439 concentrations on ADHD symptoms of the child. *J Clin Endocrinol Metab*. 2014;99:E1-
440 8.
- 441 13. Modesto T, Tiemeier H, Peeters RP, et al. Maternal Mild Thyroid Hormone Insufficiency
442 in Early Pregnancy and Attention-Deficit/Hyperactivity Disorder Symptoms in Children.
443 *JAMA Pediatr*. 2015;169:838-845.
- 444 14. Oostenbroek MHW, Kersten RHJ, Tros B, Kunst AE, Vrijkotte TGM, Finken MJJ.
445 Maternal hypothyroxinaemia in early pregnancy and problem behavior in 5-year-old
446 offspring. *Psychoneuroendocrinology*. 2017;81:29-35.
- 447 15. Lazarus JH, Bestwick JP, Channon S, et al. Antenatal thyroid screening and childhood
448 cognitive function. *N Engl J Med*. 2012;366:493-501.
- 449 16. Casey BM, Thom EA, Peaceman AM, et al. Treatment of Subclinical Hypothyroidism or
450 Hypothyroxinemia in Pregnancy. *N Engl J Med*. 2017;376:815-825.
- 451 17. Hales C, Taylor PN, Channon S, et al. Controlled Antenatal Thyroid Screening II: Effect
452 of Treating Maternal Suboptimal Thyroid Function on Child Cognition. *J Clin*
453 *Endocrinol Metab*. 2018;103:1583-1591.
- 454 18. Han C, Li C, Mao J, et al. High Body Mass Index Is an Indicator of Maternal
455 Hypothyroidism, Hypothyroxinemia, and Thyroid-Peroxidase Antibody Positivity during
456 Early Pregnancy. *Biomed Res Int*. 2015;2015:351831.
- 457 19. Knight BA, Shields BM, Hattersley AT, Vaidya B. Maternal hypothyroxinaemia in
458 pregnancy is associated with obesity and adverse maternal metabolic parameters. *Eur J*
459 *Endocrinol*. 2016;174:51-57.
- 460 20. Collares FM, Korevaar TIM, Hofman A, et al. Maternal thyroid function, prepregnancy
461 obesity and gestational weight gain-The Generation R Study: A prospective cohort study.
462 *Clin Endocrinol (Oxf)*. 2017;87:799-806.
- 463 21. Mannisto T, Surcel HM, Ruokonen A, et al. Early pregnancy reference intervals of
464 thyroid hormone concentrations in a thyroid antibody-negative pregnant population.
465 *Thyroid*. 2011;21:291-298.
- 466 22. Mosso L, Martinez A, Rojas MP, et al. Early pregnancy thyroid hormone reference
467 ranges in Chilean women: the influence of body mass index. *Clin Endocrinol (Oxf)*.
468 2016;85:942-948.
- 469 23. Laurberg P, Andersen SL, Hindersson P, Nohr EA, Olsen J. Dynamics and Predictors of
470 Serum TSH and fT4 Reference Limits in Early Pregnancy: A Study Within the Danish
471 National Birth Cohort. *J Clin Endocrinol Metab*. 2016;101:2484-2492.
- 472 24. Gaillard R, Steegers EA, Duijts L, et al. Childhood cardiometabolic outcomes of maternal
473 obesity during pregnancy: the Generation R Study. *Hypertension*. 2014;63:683-691.
- 474 25. Gaillard R, Steegers EA, Franco OH, Hofman A, Jaddoe VW. Maternal weight gain in
475 different periods of pregnancy and childhood cardio-metabolic outcomes. The
476 Generation R Study. *Int J Obes (Lond)*. 2015;39:677-685.

- 477 26. Gaillard R, Welten M, Oddy WH, et al. Associations of maternal prepregnancy body
478 mass index and gestational weight gain with cardio-metabolic risk factors in adolescent
479 offspring: a prospective cohort study. *BJOG*. 2016;123:207-216.
- 480 27. Wojcicka A, Bassett JH, Williams GR. Mechanisms of action of thyroid hormones in the
481 skeleton. *Biochimica et biophysica acta*. 2013;1830:3979-3986.
- 482 28. Bassett JH, Williams GR. Role of Thyroid Hormones in Skeletal Development and Bone
483 Maintenance. *Endocr Rev*. 2016;37:135-187.
- 484 29. Waring AC, Harrison S, Fink HA, et al. A prospective study of thyroid function, bone
485 loss, and fractures in older men: The MrOS study. *J Bone Miner Res*. 2013;28:472-479.
- 486 30. Garin MC, Arnold AM, Lee JS, Robbins J, Cappola AR. Subclinical thyroid dysfunction
487 and hip fracture and bone mineral density in older adults: the cardiovascular health
488 study. *J Clin Endocrinol Metab*. 2014;99:2657-2664.
- 489 31. Blum MR, Bauer DC, Collet TH, et al. Subclinical thyroid dysfunction and fracture risk:
490 a meta-analysis. *JAMA*. 2015;313:2055-2065.
- 491 32. Lee JS, Buzkova P, Fink HA, et al. Subclinical thyroid dysfunction and incident hip
492 fracture in older adults. *Arch Intern Med*. 2010;170:1876-1883.
- 493 33. Hales C, Channon S, Taylor PN, et al. The second wave of the Controlled Antenatal
494 Thyroid Screening (CATS II) study: the cognitive assessment protocol. *BMC Endocr*
495 *Disord*. 2014;14:95.
- 496 34. Hales C, Taylor PN, Channon S, et al. Controlled Antenatal Thyroid Screening II: effect
497 of treating maternal sub-optimal thyroid function on child behaviour. *J Clin Endocrinol*
498 *Metab*. 2019;Oct 29;pii: dgz098. Doi: 10.1210/clinem/dgz098. [Epub ahead of print]
- 499 35. Reinehr T. Obesity and thyroid function. *Mol Cell Endocrinol*. 2010;316:165-171.
- 500 36. Biondi B. Thyroid and obesity: an intriguing relationship. *J Clin Endocrinol Metab*.
501 2010;95:3614-3617.
- 502 37. Laurberg P, Knudsen N, Andersen S, Carle A, Pedersen IB, Karmisholt J. Thyroid
503 function and obesity. *Eur Thyroid J*. 2012;1:159-167.
- 504 38. Ortega FB, Lavie CJ, Blair SN. Obesity and Cardiovascular Disease. *Circ Res*.
505 2016;118:1752-1770.
- 506 39. Piche ME, Poirier P, Lemieux I, Despres JP. Overview of Epidemiology and Contribution
507 of Obesity and Body Fat Distribution to Cardiovascular Disease: An Update. *Prog*
508 *Cardiovasc Dis*. 2018;61:103-113.
- 509 40. Cooper DS, Biondi B. Subclinical thyroid disease. *Lancet*. 2012;379:1142-1154.
- 510 41. Razvi S, Jabbar A, Pingitore A, et al. Thyroid Hormones and Cardiovascular Function
511 and Diseases. *J Am Coll Cardiol*. 2018;71:1781-1796.
- 512 42. Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA. Cross sectional stature
513 and weight reference curves for the UK, 1990. *Archives of disease in childhood*.
514 1995;73:17-24.
- 515 43. Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990.
516 *Arch Dis Child*. 1995;73:25-29.
- 517 44. Wang MC, Aguirre M, Bhudhikanok GS, et al. Bone mass and hip axis length in healthy
518 Asian, black, Hispanic, and white American youths. *J Bone Miner Res*. 1997;12:1922-
519 1935.
- 520 45. Nelson DA, Simpson PM, Johnson CC, Barondess DA, Kleerekoper M. The
521 accumulation of whole body skeletal mass in third- and fourth-grade children: effects of
522 age, gender, ethnicity, and body composition. *Bone*. 1997;20:73-78.
- 523 46. Bachrach LK, Hastie T, Wang MC, Narasimhan B, Marcus R. Bone mineral acquisition
524 in healthy Asian, Hispanic, black, and Caucasian youth: a longitudinal study. *J Clin*
525 *Endocrinol Metab*. 1999;84:4702-4712.

- 526 47. Schoenau E, Neu CM, Rauch F, Manz F. Gender-specific pubertal changes in volumetric
527 cortical bone mineral density at the proximal radius. *Bone*. 2002;31:110-113.
- 528 48. Binkovitz LA, Henwood MJ. Pediatric DXA: technique and interpretation. *Pediatr*
529 *Radiol*. 2007;37:21-31.
- 530 49. Lu PW, Cowell CT, SA LL-J, Briody JN, Howman-Giles R. Volumetric bone mineral
531 density in normal subjects, aged 5-27 years. *J Clin Endocrinol Metab*. 1996;81:1586-
532 1590.
- 533 50. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone
534 densitometry data. *J Bone Miner Res*. 1992;7:137-145.
- 535 51. Ward KA, Ashby RL, Roberts SA, Adams JE, Zulf Mughal M. UK reference data for the
536 Hologic QDR Discovery dual-energy x ray absorptiometry scanner in healthy children
537 and young adults aged 6-17 years. *Arch Dis Child*. 2007;92:53-59.
- 538 52. Crabtree NJ, Shaw NJ, Bishop NJ, et al. Amalgamated Reference Data for Size-Adjusted
539 Bone Densitometry Measurements in 3598 Children and Young Adults-the ALPHABET
540 Study. *J Bone Miner Res*. 2017;32:172-180.
- 541 53. O'Rourke MF, Pauca A, Jiang XJ. Pulse wave analysis. *Br J Clin Pharmacol*.
542 2001;51:507-522.
- 543 54. Hickson SS, Butlin M, Broad J, Avolio AP, Wilkinson IB, McEniery CM. Validity and
544 repeatability of the Vicorder apparatus: a comparison with the SphygmoCor device.
545 *Hypertens Res*. 2009;32:1079-1085.
- 546 55. Davies JM, Bailey MA, Griffin KJ, Scott DJ. Pulse wave velocity and the non-invasive
547 methods used to assess it: Complior, SphygmoCor, Arteriograph and Vicorder. *Vascular*.
548 2012;20:342-349.
- 549 56. Shahin Y, Barakat H, Barnes R, Chetter I. The Vicorder device compared with
550 SphygmoCor in the assessment of carotid-femoral pulse wave velocity in patients with
551 peripheral arterial disease. *Hypertens Res*. 2013;36:208-212.
- 552 57. Kis E, Cseprekal O, Kerti A, et al. Measurement of pulse wave velocity in children and
553 young adults: a comparative study using three different devices. *Hypertens Res*.
554 2011;34:1197-1202.
- 555 58. Kracht D, Shroff R, Baig S, et al. Validating a new oscillometric device for aortic pulse
556 wave velocity measurements in children and adolescents. *Am J Hypertens*.
557 2011;24:1294-1299.
- 558 59. Pucci G, Cheriyan J, Hubsch A, et al. Evaluation of the Vicorder, a novel cuff-based
559 device for the noninvasive estimation of central blood pressure. *J Hypertens*. 2013;31:77-
560 85.
- 561 60. Muller I, Taylor PN, Daniel RM, et al. Supplemental data of "Controlled Antenatal
562 Thyroid Screening (CATS) study II: Effects of treating maternal sub-optimal gestational
563 thyroid function on anthropometric, bone and cardiometabolic outcomes". Figshare
564 Digital Repository. Deposited 1 January 2020.
565 <http://doi.org/10.6084/m9.figshare.11492289>.
- 566 61. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. *Int J*
567 *Pediatr Obes*. 2006;1:11-25.
- 568 62. Han JC, Lawlor DA, Kimm SY. Childhood obesity. *Lancet*. 2010;375:1737-1748.
- 569 63. Kahn BB, Flier JS. Obesity and insulin resistance. *The Journal of clinical investigation*.
570 2000;106:473-481.
- 571 64. Franssen R, Monajemi H, Stroes ES, Kastelein JJ. Obesity and dyslipidemia. *Med Clin*
572 *North Am*. 2011;95:893-902.
- 573 65. Ye J. Mechanisms of insulin resistance in obesity. *Front Med*. 2013;7:14-24.
- 574 66. Woeber KA. Levothyroxine therapy and serum free thyroxine and free triiodothyronine
575 concentrations. *J Endocrinol Invest*. 2002;25:106-109.

- 576 67. Lips DJ, van Reisen MT, Voigt V, Venekamp W. Diagnosis and treatment of
577 levothyroxine pseudomalabsorption. *Neth J Med.* 2004;62:114-118.
- 578 68. Knudsen N, Laurberg P, Rasmussen LB, et al. Small differences in thyroid function may
579 be important for body mass index and the occurrence of obesity in the population. *J Clin*
580 *Endocrinol Metab.* 2005;90:4019-4024.
- 581 69. Fox CS, Pencina MJ, D'Agostino RB, et al. Relations of thyroid function to body weight:
582 cross-sectional and longitudinal observations in a community-based sample. *Arch Intern*
583 *Med.* 2008;168:587-592.
- 584 70. Svare A, Nilsen TI, Bjoro T, Asvold BO, Langhammer A. Serum TSH related to
585 measures of body mass: longitudinal data from the HUNT Study, Norway. *Clin*
586 *Endocrinol (Oxf).* 2011;74:769-775.
- 587 71. Taylor PN, Razvi S, Pearce SH, et al. Clinical review: A review of the clinical
588 consequences of variation in thyroid function within the reference range. *J Clin*
589 *Endocrinol Metab.* 2013;98:3562-3571.
- 590 72. Reinehr T, Andler W. Thyroid hormones before and after weight loss in obesity. *Arch Dis*
591 *Child.* 2002;87:320-323.
- 592 73. Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines.
593 Laboratory support for the diagnosis and monitoring of thyroid disease. *Thyroid.*
594 2003;13:3-126.
- 595 74. al-Adsani H, Hoffer LJ, Silva JE. Resting energy expenditure is sensitive to small dose
596 changes in patients on chronic thyroid hormone replacement. *J Clin Endocrinol Metab.*
597 1997;82:1118-1125.
- 598 75. Feller M, Snel M, Moutzouri E, et al. Association of Thyroid Hormone Therapy With
599 Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical
600 Hypothyroidism: A Systematic Review and Meta-analysis. *JAMA.* 2018;320:1349-1359.
- 601 76. Stott DJ, Gussekloo J, Kearney PM, et al. Study protocol; Thyroid hormone Replacement
602 for Untreated older adults with Subclinical hypothyroidism - a randomised placebo
603 controlled Trial (TRUST). *BMC Endocr Disord.* 2017;17:6.
- 604 77. Zhao M, Liu L, Wang F, et al. A Worthy Finding: Decrease in Total Cholesterol and
605 Low-Density Lipoprotein Cholesterol in Treated Mild Subclinical Hypothyroidism.
606 *Thyroid.* 2016;26:1019-1029.
- 607

609 **FIGURE 1. Flow chart of study population**




610
 611 The recruitment of study participants initially started with the CATS-I study, assessing child
 612 cognition at 3 years of age (15). A UK-only subset of the original population and an
 613 additional third group (NGTF) were involved in the subsequent follow-up CATS-II study,
 614 assessing child cognition (17) and behavior (34) at 9 years of age. Only CATS-II children
 615 and paired mothers attending visits at the research center were included in the present study
 616 and assessed for cardiovascular, metabolic and bone measurements.

617 * = Children tended to participate less in this study compared with their mothers, except for
 618 one mother in the SGTF-U group, refusing to be included in the study but agreeing for her
 619 son to participate.

620 **BMI** = body mass index. **CATS** = Controlled Antenatal Thyroid Screening study. **DXA** =
 621 dual-energy x-ray absorptiometry. **IQ** = intelligence quotient. **NGTF** = normal gestational
 622 thyroid function. **SDS** = standard deviation scores. **SGTF-T** = suboptimal gestational thyroid
 623 function treated with levothyroxine during pregnancy (Treated). **SGTF-U** = suboptimal
 624 gestational thyroid function not treated with levothyroxine during pregnancy (Untreated).
 625 **UHW** = University Hospital of Wales (research center).

626 **FIGURE 2. Comparison of body composition at CATS-I and CATS-II studies among**
 627 **women**



628
 629 **BMI** = body mass index. **CATS** = Controlled Antenatal Thyroid Screening study. **DXA** =
 630 dual-energy x-ray absorptiometry. **NGTF** = normal gestational thyroid function. **SGTF-T** =
 631 suboptimal gestational thyroid function treated with levothyroxine during pregnancy
 632 (Treated). **SGTF-U** = suboptimal gestational thyroid function not treated with levothyroxine
 633 during pregnancy (Untreated).
 634 Reported p values refer to the comparisons between NGTF and SGTF-U.

635
 636

Table 1. Anthropometric, bone and cardiometabolic outcomes: children

	TOT N = 326	NGTF N = 191	SGTF-U N = 57	SGTF-T N = 78	p1U	p1T	p2
Age (years)	9.3 ± 1.0	9.6 ± 0.7	9.0 ± 1.1	8.8 ± 1.1	<0.001	<0.001	0.485
Female children N (%)	158 (48.5%)	88 (46.1%)	32 (56.1%)	38 (48.7%)	0.227	0.788	0.486
Height (cm)	136.7 ± 7.9	138.5 ± 7.3	133.5 ± 8.7	134.8 ± 7.4	0.051	0.779	0.089
BMI (kg/m ²)	17.2 [15.8 - 19.2]	17.3 [15.9 - 19.5]	17.0 [15.8 - 19.3]	16.8 [15.5 - 18.7]	0.587	0.822	0.464
BMI-SDS UK1990	0.49 ± 1.15	0.48 ± 1.15	0.57 ± 1.15	0.46 ± 1.15	0.646	0.763	0.481
<i>DXA SCAN¹</i>							
WBLH Lean Mass (kg)	19.7 ± 3.5	20.3 ± 3.3	18.6 ± 3.6	19.0 ± 3.6	0.395	0.808	0.454
WBLH Fat Mass (kg)	8.36 [6.12 - 11.89]	8.67 [6.27 - 12.90]	8.71 [6.26 - 10.85]	7.46 [5.84 - 10.46]	0.979	0.573	0.553
WBLH Fat Mass (%)	31.8 ± 7.9	31.9 ± 7.8	32.6 ± 8.1	30.8 ± 7.9	0.617	0.475	0.279
LS-BMD-H (SDS)	0.33 ± 1.00	0.28 ± 0.97	0.28 ± 1.00	0.50 ± 1.08	0.721	0.302	0.424
LS-BMD-A (SDS)	0.23 ± 1.01	0.16 ± 0.97	0.19 ± 0.99	0.43 ± 1.10	0.751	0.261	0.403
LS-BMAD-A (SDS)	0.35 ± 1.08	0.30 ± 1.08	0.29 ± 1.04	0.53 ± 1.12	0.950	0.214	0.384
LS-BMAD-W (SDS)	0.27 ± 1.07	0.22 ± 1.07	0.22 ± 1.03	0.43 ± 1.1	0.948	0.223	0.471
FN-BMD-H (SDS)	0.49 ± 1.04	0.00 ± 0.95	0.02 ± 1.17	0.19 ± 1.14	0.900	0.358	0.732
FN-BMAD-W (SDS)	0.21 ± 0.99	0.16 ± 0.88	0.27 ± 1.26	0.29 ± 1.01	0.255	0.314	0.755
WBLH-BMD-H (SDS)	-0.83 ± 0.86	-0.80 ± 0.80	-0.93 ± 0.87	-0.85 ± 0.99	0.459	0.837	0.973
WBLH-BMD-A (SDS)	-0.87 ± 0.96	-0.87 ± 0.90	-0.98 ± 0.95	-0.79 ± 1.10	0.339	0.850	0.546
<i>BIOCHEMICAL²</i>							
TSH (mU/L)	1.77 [1.42 - 2.52]	1.64 [1.38 - 2.31]	1.80 [1.41 - 2.29]	1.81 [1.66 - 2.76]	0.511	0.305	0.764
FT4 (pmol/L)	14.69 ± 1.48	14.20 ± 1.38	15.39 ± 1.65	14.82 ± 1.25	0.098	0.597	0.335
FT3 (pmol/L)	5.60 ± 0.64	5.43 ± 0.63	5.87 ± 0.45	5.65 ± 0.73	0.158	0.938	0.290
TPOAb Positive/Total (%)	3/83 (3.6)	1/39 (2.6)	1/21 (4.8)	1/23 (4.3)	1.000	1.000	1.000
Cholesterol TOT (mmol/L)	4.33 ± 0.60	4.35 ± 0.63	4.41 ± 0.62	4.22 ± 0.54	0.398	0.887	0.403
Cholesterol HDL (mmol/L)	1.20 ± 0.26	1.22 ± 0.27	1.26 ± 0.29	1.10 ± 0.21	0.178	0.566	0.048
Triglyceride (mmol/L)	0.71 [0.60 - 0.90]	0.70 [0.50 - 1.00]	0.80 [0.62 - 0.88]	0.68 [0.60 - 0.89]	0.789	0.509	0.374
Insulin (µIU/mL)	4.45 [3.30 - 5.95]	4.90 [3.60 - 6.90]	4.40 [3.30 - 5.70]	3.85 [3.3 - 5.1]	0.385	0.272	0.950
Adiponectin (ng/mL)	13.49 ± 5.19	12.36 ± 4.44	14.75 ± 5.41	14.25 ± 5.96	0.368	0.554	0.703
<i>CARDIOVASCULAR³</i>							
SP (mmHg)	125.4 ± 12.9	124.8 ± 12.9	126.9 ± 10.4	127.2 ± 14.8	0.330	0.840	0.284
DP (mmHg)	63.0 ± 7.9	63.0 ± 7.7	61.8 ± 9.0	64.1 ± 8.0	0.497	0.682	0.228
AI (%)	7.33 [3.67 - 11.67]	7.33 [3.42 - 11.17]	10.67 [4.00 - 14.00]	7.00 [5.00 - 11.33]	0.363	0.911	0.454
PWV (m/s)	6.22 ± 0.65	6.22 ± 0.68	6.22 ± 0.51	6.17 ± 0.61	0.919	0.903	0.452

The results are presented as mean \pm SD or median [IQR], if Normally- or non-Normally distributed, respectively.

¹ = Data available for 323 subjects; ² = Data available for 83 subjects; ³ = Data available for 189 subjects

A = Alphabet study reference cohort. **AI** = augmentation index. **BMAD** = bone mineral apparent density. **BMD** = bone mineral density. **BMI** = body mass index. **BMI-SDS** = standard deviation score of body mass index. **DP** = diastolic blood pressure. **DXA** = dual-energy x-ray absorptiometry. **FN** = femoral neck. **FT3** = free-triiodothyronine. **FT4** = free-thyroxine. **H** = Hologic manufacturer reference cohort. **LS** = lumbar spine (from L1 to L4). **NGTF** = children of women with normal gestational thyroid function. **PWV** = aortic pulse wave velocity. **SGTF-T** = children of women with suboptimal gestational thyroid function treated with levothyroxine during pregnancy (Treated). **SGTF-U** = children of women with suboptimal gestational thyroid function not treated with levothyroxine during pregnancy (Untreated). **SDS** = standard deviation score. **SP** = systolic blood pressure. **TPOAb** = autoantibodies to thyroid peroxidase. **TSH** = thyrotropin. **W** = Ward study reference cohort. **WBLH** = whole body less head.
p1U = NGTF vs SGTF-U. **p1T** = NGTF vs SGTF-T. **p2** = SGTF-U vs SGTF-T.

Table 2. Anthropometric, bone and cardiometabolic outcomes: mothers

	TOT N = 332	NGTF N = 197	SGTF-U N = 56	SGTF-T N = 79	p1U	p1T	p2
Age (years)	41.2 ± 5.3	41.8 ± 5.5	40.9 ± 4.7	39.7 ± 4.8	0.252	0.002	0.144
Height (cm)	164.0 ± 6.4	164.3 ± 6.1	163.2 ± 5.7	164.1 ± 7.6	0.213	0.580	0.402
BMI CATS-I (kg/m ²)	25.4 [22.7 - 28.7]	25.0 [22.4 - 28.3]	26.0 [23.4 - 30.1]	25.6 [23.0 - 29.2]	0.111	0.112	0.806
BMI (kg/m ²)	26.1 [23.1 - 30.3]	25.8 [22.9 - 30.0]	28.3 [24.6 - 32.6]	25.8 [23.1 - 29.8]	0.029	0.672	0.139
DXA SCAN¹							
WBLH Lean Mass (kg)	39.2 ± 5.6	38.9 ± 5.2	40.0 ± 5.7	39.3 ± 6.4	0.291	0.698	0.661
WBLH Fat Mass (kg)	28.3 ± 10.7	27.5 ± 10.3	31.5 ± 11.4	27.8 ± 10.7	0.016	0.791	0.084
WBLH Fat Mass (%)	40.7 ± 7.3	40.2 ± 7.2	42.8 ± 7.2	40.4 ± 7.4	0.017	0.784	0.072
LS-BMD (g/cm ²)	1.07 ± 0.12	1.06 ± 0.11	1.06 ± 0.12	1.08 ± 0.12	0.834	0.150	0.541
FN-BMD (g/cm ²)	0.84 ± 0.11	0.83 ± 0.11	0.85 ± 1.24	0.83 ± 0.11	0.297	0.949	0.321
BIOCHEMICAL²							
TSH CATS-I (mU/L)	1.66 [0.94 - 3.37]	1.22 [0.77 - 1.79]	3.37 [1.22 - 4.45]	4.21 [2.33 - 5.23]	<0.001	<0.001	0.098
TSH (mU/L)	1.64 [1.10 - 2.52]	1.54 [1.12 - 2.07]	2.45 [1.43 - 3.50]	1.68 [0.89 - 2.96]	0.015	0.474	0.070
FT4 (pmol/L)	14.0 ± 2.3	13.6 ± 1.7	13.9 ± 2.8	15.0 ± 2.9	0.471	<0.001	0.200
FT3 (pmol/L)	4.13 ± 0.51	4.15 ± 0.45	4.07 ± 0.53	4.11 ± 0.63	0.239	0.299	0.428
TPOAb Positive/Total (%)	79/294 (26.9)	21/173 (12.1)	20/50 (40.0)	38/71 (53.5)	<0.001	<0.001	0.196
Cholesterol TOT (mmol/L)	4.93 ± 0.87	4.91 ± 0.83	5.07 ± 0.93	4.88 ± 0.94	0.224	0.708	0.506
Cholesterol HDL (mmol/L)	1.29 ± 0.32	1.32 ± 0.31	1.24 ± 0.33	1.24 ± 0.34	0.125	0.101	0.785
Triglyceride (mmol/L)	0.90 [0.70 - 1.20]	0.90 [0.70 - 1.10]	1.01 [0.78 - 1.40]	0.80 [0.64 - 1.29]	0.041	0.730	0.193
Insulin (μIU/mL)	5.90 [4.40 - 7.80]	5.90 [4.60 - 7.80]	6.30 [4.40 - 9.15]	5.50 [3.85 - 7.15]	0.231	0.073	0.046
Adiponectin (ng/mL)	10.59 ± 4.80	10.63 ± 4.71	10.54 ± 4.65	10.52 ± 5.19	0.964	0.988	0.872
CARDIOVASCULAR³							
SP (mmHg)	125.7 ± 12.8	126.6 ± 12.9	124.6 ± 9.3	122.1 ± 14.4	0.569	0.155	0.220
DP (mmHg)	70.3 ± 8.3	70.6 ± 8.4	70.8 ± 8.0	68.7 ± 7.9	0.966	0.409	0.578
AI (%)	17.5 ± 7.2	18.1 ± 7.5	15.6 ± 4.8	16.5 ± 7.00	0.186	0.588	0.494
PWV (m/s)	8.80 [7.50 - 10.95]	9.28 [7.66 - 11.17]	7.87 [7.37 - 9.47]	7.93 [6.83 - 9.77]	0.491	0.101	0.605

The results are presented as mean ± SD or median [IQR], if Normally- or non-Normally distributed, respectively. All values refer to the Controlled Antenatal Thyroid Screening (CATS) study II analysis, except for BMI CATS-I and TSH CATS-I, relative to CATS study I analysis.

¹ = Data available for 327 subjects; ² = Data available for 294 subjects; ³ = Data available for 194 subjects.

AI = augmentation index. **BMD** = bone mineral density. **BMI** = body mass index. **DP** = diastolic blood pressure. **DXA** = dual-energy x-ray absorptiometry. **FN** = femoral neck. **FT3** = free-triiodothyronine. **FT4** = free-thyroxine. **LS** = lumbar spine (from L1 to L4). **NGTF** = normal gestational thyroid function. **PWV** = aortic pulse wave velocity. **SGTF-T** = suboptimal gestational thyroid function treated with levothyroxine during pregnancy (Treated). **SGTF-U** = suboptimal gestational thyroid function not treated with levothyroxine during pregnancy (Untreated). **SP** = systolic blood pressure. **TPOAb** = autoantibodies to thyroid peroxidase. **TSH** = thyrotropin. **WBLH** = whole body less head. **p1U** = NGTF vs SGTF-U. **p1T** = NGTF vs SGTF-T. **p2** = SGTF-U vs SGTF-T.

Table 3. Levothyroxine treatment

	TOT N = 332	NGTF N = 197	SGTF-U N = 57	SGTF-T N = 79	p
Never	176 (53.0%)	139 (70.6%)	38 (66.7%)	0 (0.0%)	<0.001
Yes stopped	36 (10.8%)	3 (1.5%)	0 (0.0%)	33 (41.8%)	<0.001
Yes current	65 (19.6%)	8 (4.1%)	16 (28.1%)	41 (51.9%)	0.008
Unknown	55 (16.6%)	47 (23.8%)	3 (5.2%)	5 (6.3%)	1.000

History of women's levothyroxine treatment collected at recruitment into the Controlled Antenatal Thyroid Screening study II (CATS-II).

NGTF = normal gestational thyroid function. **SGTF-T** = suboptimal gestational thyroid function treated with levothyroxine during pregnancy (Treated). **SGTF-U** = suboptimal gestational thyroid function not treated with levothyroxine during pregnancy (Untreated). **Yes stopped** = taken in the past but not currently. **Yes current** = started in the past and currently still on treatment.

Reported p values refer to the comparisons between SGTF-U and SGTF-T

Supplemental Table 1. Models used for analysis

MODEL	INCLUDED VARIABLES	PARAMETERS EVALUATED	COMPARISON
1	None (unadjusted)	Age	All
2	Age, ethnicity, social class, smoking during pregnancy	All numerical parameters except age	NGTF vs SGTF-U (p1U) NGTF vs SGTF-T (p1T)
3	Age, ethnicity, social class, smoking during pregnancy, baseline (CATS-I) TSH, baseline (CATS-I) FT4	All numerical parameters except age	SGTF-U vs SGTF-T (p2) SGTF-TOpt vs SGTF-TOver (p)

CATS-I = Controlled Antenatal Thyroid Screening study I. **FT4** = free-thyroxine. **NGTF** = normal gestational thyroid function. **SGTF-T** = suboptimal gestational thyroid function treated with levothyroxine during pregnancy (Treated). **SGTF-TOpt** = SGTF-T optimally treated with levothyroxine. **SGTF-TOver** = SGTF-T over-treated with levothyroxine. **SGTF-U** = suboptimal gestational thyroid function not treated with levothyroxine during pregnancy (Untreated). **TSH** = thyrotropin.

Supplemental Table 2. Levothyroxine over-treatment sub-analysis: mothers

	SGTF-T_{opt} N = 58	SGTF-T_{over} N = 21	P
Age (years)	40.3 ± 4.8	38.1 ± 4.7	0.069
Height (cm)	164.9 ± 7.4	161.8 ± 7.7	0.032
BMI CATS-I (kg/m ²)	26.4 [23.8 - 32.0]	23.2 [21.3-25.7]	0.001
BMI (kg/m ²)	26.7 [23.9 - 30.9]	23.5 [22.2 - 25.3]	0.002
<i>DXA SCAN</i>¹			
WBLH Lean Mass (kg)	40.9 ± 6.3	34.8 ± 4.3	<0.001
WBLH Fat Mass (kg)	30.1 ± 11.1	21.9 ± 7.0	0.007
WBLH Fat Mass (%)	41.3 ± 7.2	37.9 ± 7.6	0.180
LS-BMD (g/cm ²)	1.10 ± 0.12	1.05 ± 0.11	0.198
FN-BMD (g/cm ²)	0.85 ± 0.12	0.80 ± 0.73	0.111
<i>BIOCHEMICAL</i>²			
TSH CATS-I (mU/L)	4.09 [1.94 - 5.30]	4.40 [3.75 - 4.62]	0.379
TSH (mU/L)	1.52 [0.86 - 2.96]	1.76 [1.22 - 3.32]	0.962
FT4 (pmol/L)	15.06 ± 2.79	14.73 ± 3.31	0.762
FT3 (pmol/L)	4.13 ± 0.66	4.05 ± 0.56	0.867
TPOAb Positive/Total (%)	23/51	10/20	0.794
Cholesterol TOT (mmol/L)	4.81 ± 0.85	5.07 ± 1.16	0.073
Cholesterol HDL (mmol/L)	1.15 ± 0.33	1.44 ± 0.27	0.002
Triglyceride (mmol/L)	0.91 [0.68 - 1.29]	0.80 [0.60 - 1.21]	0.562
Insulin (μIU/mL)	5.50 [3.90 - 7.50]	5.65 [3.75 - 6.85]	0.772
Adiponectin (ng/mL)	10.16 ± 5.70	11.44 ± 3.53	0.727
<i>CARDIOVASCULAR</i>³			
SP (mmHg)	127.6 ± 13.5	113.7 ± 11.7	0.036
DP (mmHg)	70.4 ± 8.0	66.0 ± 7.3	0.767
AI (%)	17.8 ± 6.3	14.6 ± 7.9	0.746
PWV (m/s)	8.05 [6.83 - 13.03]	7.13 [6.80 - 8.17]	0.855

The results are presented as mean ± SD or median [IQR], if having a normal or non-normal distribution, respectively. All values refer to the Controlled Antenatal Thyroid Screening (CATS) study II analysis, except for BMI CATS-I and TSH CATS-I, relative to CATS study I analysis.

¹ = Data available for 56 SGTF-T_{opt} and 21 SGTF-T_{over} subjects;

² = Data available for 51 SGTF-T_{opt} and 20 SGTF-T_{over} subjects;

³ = Data available for 17 SGTF-T_{opt} and 11 SGTF-T_{over} subjects.

AI = augmentation index. **BMD** = bone mineral density. **BMI** = body mass index. **DP** = diastolic blood pressure. **DXA** = dual-energy x-ray absorptiometry. **FN** = femoral neck. **FT3** = free-triiodothyronine. **FT4** = free-thyroxine. **LS** = lumbar spine (from L1 to L4). **PWV** = aortic pulse wave velocity. **SGTF-T_{opt}** = suboptimal gestational thyroid function optimally treated with levothyroxine during pregnancy. **SGTF-T_{over}** = suboptimal gestational thyroid function over-treated with levothyroxine during pregnancy. **SP** = systolic blood pressure. **TPOAb** = autoantibodies to thyroid peroxidase. **TSH** = thyrotropin. **WBLH** = Whole body less head.

Supplemental Table 3. Levothyroxine over-treatment sub-analysis: children

	SGTF-Topt N = 57	SGTF-Tover N = 21	p	p⁴	p⁵
Age (years)	8.8 ± 1.2	9.0 ± 0.9	0.516	NA	NA
Female children N (%)	30 (52.6%)	8 (38.1%)	0.260	NA	NA
Height (cm)	135.1 ± 7.7	132.9 ± 8.1	0.016	NA	0.044
BMI (kg/m ²)	17.6 [16.0 - 19.1]	15.2 [14.9 - 16.7]	0.005	NA	0.041
BMI-SDS UK1990 (SDS)	0.70 ± 1.07	-0.19 ± 1.14	0.001	NA	0.006
DXA SCAN¹					
WBLH Lean Mass (kg)	19.6 ± 3.3	17.6 ± 3.9	0.004	NA	0.109
WBLH Fat Mass (kg)	9.66 ± 4.64	7.22 ± 4.19	0.087	NA	0.298
WBLH Fat Mass (%)	31.9 ± 8.0	28.0 ± 7.1	0.234	NA	0.511
LS-BMD-H (SDS)	0.59 ± 1.00	0.26 ± 1.24	0.174	0.394	0.603
LS-BMD-A (SDS)	0.51 ± 1.07	0.23 ± 1.21	0.217	0.449	0.669
LS-BMAD-A (SDS)	0.57 ± 1.07	0.42 ± 1.25	0.405	0.423	0.679
LS-BMAD-W (SDS)	0.46 ± 1.05	0.33 ± 1.27	0.455	0.467	0.702
FN-BMD-H (SDS)	0.33 ± 1.05	-0.19 ± 1.30	0.037	0.164	0.272
FN-BMAD-W (SDS)	0.31 ± 1.03	0.23 ± 0.99	0.952	0.803	0.988
WBLH-BMD-H (SDS)	-0.62 ± 0.80	-1.44 ± 1.19	0.002	0.036	0.216
WBLH-BMD-A (SDS)	-0.57 ± 0.96	-1.39 ± 1.26	0.002	0.042	0.193
BIOCHEMICAL²					
TSH (mU/L)	1.81 [1.66 - 2.76]	1.82 [1.55 - 2.41]	0.540	NA	0.526
FT4 (pmol/L)	14.91 ± 1.24	14.40 ± 1.40	0.251	NA	0.280
FT3 (pmol/L)	5.83 ± 0.55	4.77 ± 0.92	0.036	NA	0.051
TPOAb Positive/Total (%)	1/19 (5.3)	0/4 (0.0)	1.000	NA	NA
Cholesterol TOT (mmol/L)	4.24 ± 0.53	4.13 ± 0.68	0.197	NA	0.218
Cholesterol HDL (mmol/L)	1.08 ± 0.21	1.20 ± 0.14	0.717	NA	0.332
Triglyceride (mmol/L)	0.68 [0.60 - 0.90]	0.65 [0.55 - 0.75]	0.484	NA	0.505
Insulin (µIU/mL)	3.70 [3.30 - 5.60]	4.00 [2.80 - 4.60]	0.824	NA	0.544
Adiponectin (ng/mL)	13.91 ± 5.92	15.87 ± 6.76	0.292	NA	0.298
CARDIOVASCULAR³					
SP (mmHg)	125.3 ± 16.9	130.5 ± 10.2	0.768	NA	0.260
DP (mmHg)	64.2 ± 8.4	63.9 ± 7.8	0.586	NA	0.637
AI (%)	6.67 [3.67 - 11.33]	7.12 [7.00 - 9.00]	0.367	NA	0.412
PWV (m/s)	6.03 ± 0.46	6.37 ± 0.77	0.041	NA	0.035

The results are presented as mean ± SD or median [IQR], if having a normal or non-normal distribution, respectively.

¹ = Data available for 56 SGTF-T_{opt} and 21 SGTF-T_{over} subjects;

² = Data available for 19 SGTF-T_{opt} and 4 SGTF-T_{over} subjects;


³ = Data available for 18 SGTF-T_{opt} and 10 SGTF-T_{over} subjects;

⁴ = linear regression adjusted also for child's height;

⁵ = linear regression adjusted also for the corresponding maternal parameter. For BMI SDS used mother's BMI. For bone DXA scan standard deviation scores used the maternal BMD of the same area.

A = Alphabet study reference cohort. **AI** = augmentation index. **BMAD** = bone mineral apparent density. **BMD** = bone mineral density. **BMI** = body mass index. **BMI-SDS** = standard deviation score of body mass index. **DP** = diastolic blood pressure. **DXA** = dual-energy x-ray absorptiometry. **FN** = femoral neck. **FT3** = free-triiodothyronine. **FT4** = free-thyroxine. **LS** = lumbar spine (from L1 to L4). **NA** = Not Applicable. **PWV** = aortic pulse wave velocity. **SGTF-Topt** = children of women with suboptimal gestational thyroid function optimally treated with levothyroxine during pregnancy. **SGTF-Tover** = children of women with suboptimal gestational thyroid function over-treated with levothyroxine during pregnancy. **SDS** = standard deviation score. **SP** = systolic blood pressure. **TPOAb** = autoantibodies to thyroid peroxidase. **TSH** = thyrotropin. **W** = Ward study reference cohort. **WBLH** = whole body less head.

Supplemental Figure 1. Correlation between BMI and TSH: mothers



Panel A: entire women cohort at the Controlled Antenatal Thyroid Screening study I (CATS-I). **Panel B:** entire women cohort at the Controlled Antenatal Thyroid Screening study II (CATS-II). **Panel C:** women cohort at CATS-II excluding those with suboptimal gestational thyroid function treated with levothyroxine during pregnancy (SGTF-T).